JPH0465813B2 - - Google Patents
Info
- Publication number
- JPH0465813B2 JPH0465813B2 JP58158741A JP15874183A JPH0465813B2 JP H0465813 B2 JPH0465813 B2 JP H0465813B2 JP 58158741 A JP58158741 A JP 58158741A JP 15874183 A JP15874183 A JP 15874183A JP H0465813 B2 JPH0465813 B2 JP H0465813B2
- Authority
- JP
- Japan
- Prior art keywords
- specific gravity
- powder
- tablets
- bulk specific
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
Description
本発明は、粉体流動性に優れ、打錠成型機への
定量供給性が良く、重量変動の少ない錠剤を得る
ことのできる粉粒体組成物に関するものであり、
詳しくは特定範囲の嵩比重を有する繊維素グリコ
ール酸カルシウムを崩壊剤として配合してなる粉
粒体組成物に関するものである。
錠剤などの固形薬剤は経口摂取後、胃や腸の消
化液中で崩壊し、薬効成分を放出し、胃や腸の壁
面から人体に薬効成分を吸収させるものである
が、取扱い時は形状が安定して保持されながら、
消化液中での崩壊を充分に行わせるため、多くの
場合崩壊剤が配合使用される。繊維素グリコール
酸カルシウムは医薬用崩壊剤として最も多用され
ているが、無味、無臭、白色であつて崩壊性、膨
潤倍率、圧縮成形性などが良好であるなどの利点
を有するためであり、カルボキシメチルセルロー
スカルシウムとして日本薬局方に収載されECG
−505の商品名(ニチリン化学工業株式会社製造)
で市販されている。その標準的な性質は水中1重
量%分散液の媒体のPHは5〜5.5で、粒度は200メ
ツシユ通過、無水グルコース単位当りのカルボキ
シメチル基の置換度は0.55〜0.6である。
繊維素グリコール酸カルシウムは錠剤の場合、
全体の重量に対して2〜15%使用してこれに崩壊
性を付与するものであるが、粉粒体組成物の中で
は比較的流動性が悪く、径3〜20mm、深さ7〜10
mmの打錠機中でブリツジを形成しやすく、そのた
めに原料粉粒体の定量供給性を低くする傾向があ
る。この定量供給性の低いことは、錠剤重量、薬
効成分量の変動や錠剤硬度の変動の原因となるも
のであつて、作業性ならびに品質管理上好ましく
ない。
この発明の発明者らは、この粉粒体組成物の定
量供給性が使用する繊維素グリコール酸カルシウ
ムの嵩比重の値に依存するところが大きいことを
見出し、嵩比重の大きな繊維素グリコール酸カル
シウムを使用した場合に錠剤成型用粉粒体組成物
の定量供給性が良好であり、重量変動、硬度の変
動のない錠剤が得られることを認め本発明に到達
した。
本発明に使用する嵩比重の大きい繊維素グリコ
ール酸カルシウムの製造法も、基本的には特公昭
43−7960号公報に示された方法に従い、繊維素グ
リコール酸の遊離酸型のものに湿潤状態で炭酸カ
ルシウムを作用させることによつて得られるが原
料繊維素グリコール酸の無水グルコース残基あた
りの置換度が高く、且つ中和度も高PH域に設定す
ることによつて嵩比重の大きい繊維素グリコール
酸カルシウムを得ることができる。また中和反応
時の撹拌シエアーを大きくし、中和に使用する炭
酸カルシウムの1/3程度を水酸化カルシウムでお
きかえることも嵩比重の大きな繊維素グリコール
酸カルシウムを得るのに好都合な条件である。
本発明に使用する繊維素グリコール酸カルシウ
ムの嵩比重は550g/以上900g/以下であ
る。嵩比重550g/以下であれば従来の市販品
を用いた場合と同様である。一方嵩比重は大きい
方がよいが900g/以上は製造が困難であり、
また粉粒体組成物中の他の成分との均一混合性が
かえつて悪くなる可能性がある。ここでいう嵩比
重とは粉体試料を次の方法で測定した値である。
嵩比重測定方法
200mlメスシリンダーを用意し、粉体試料を200
ml目盛まで徐々に投入し、層積する。メスシリン
ダーの底部と床面の距離が5cmになるよう持ち上
げて手を離し、シリンダーを落下させる。この操
作を10回繰り返した後の容積(ml)を読み取つた
後、粉体試料の重量を量る。
嵩比重(g/)=
〔重量(g)/容積(ml)〕×1000
以下に実施例によつて本発明を具体的に説明す
る。
実施例1及び比較例1
嵩比重の異なる繊維素グリコール酸カルシウム
を崩壊剤として使用し、薬効成分としてアスコル
ビン酸、賦形剤として微結晶セルロース(アビセ
ルPH101、旭化成製)を混合した粉粒体組成物か
ら直打法によつて錠剤を成型した。粉粒体組成及
び打錠条件は次の通りである。
粉粒体組成
アスコルビン酸 50.0
アビセル(200mesh不通過) 42.0
崩壊剤 5.0
タルク 2.5ステアリン酸マグネシウム 0.5
100.0重量%
打錠条件
打錠機:回転式粉末成形機No.8F−3B 菊水製作
所製
成型条件:錠径7.6mm 厚み約4.0mm
成型機への粉体供給はすべてオープンフイード
とし、粉末充填深さ並びに打錠圧の水準をかえて
打錠し、錠剤の平均重量と重量偏差(n=30)、
平均硬度と硬度偏差(n=5)、磨損度、崩壊性
の各測定を行つた。但し硬度、磨損度と崩壊性の
測定法は次の通りである。
硬 度:モンサント硬度計
磨損度:萱垣式磨損度試験機 25回転 20分間処
理 100個の錠剤を処理し粉末化したものの重
量を百分率で示す。
崩壊性:日本薬局方準拠崩壊度試験機(富山産業
株式会社)測定温度:37±2℃
試験液:水及び局方第1液(人工胃液)
n=10:崩壊に要する時間の平均値で示す。
(秒)
第1表に崩壊剤として使用した繊維素グリコー
ル酸カルシウムの性状を示す。
(*但し、中和度は試料を100倍の蒸留水に分散さ
せたときの媒体のPHで表わす。)
The present invention relates to a powder composition that has excellent powder fluidity, has good quantitative feedability to a tablet molding machine, and is capable of producing tablets with little weight fluctuation.
Specifically, the present invention relates to a powder composition containing cellulose calcium glycolate having a bulk specific gravity within a specific range as a disintegrant. After solid drugs such as tablets are ingested, they disintegrate in the digestive juices of the stomach and intestines, releasing their medicinal ingredients, which are then absorbed into the human body through the walls of the stomach and intestines. While being held stable,
In order to ensure sufficient disintegration in digestive fluids, a disintegrant is often used. Calcium glycolate is most commonly used as a pharmaceutical disintegrant because it has advantages such as being tasteless, odorless, white, and having good disintegration properties, swelling ratio, compression moldability, etc. Listed in the Japanese Pharmacopoeia as methylcellulose calcium and ECG
-505 product name (manufactured by Nichirin Chemical Industry Co., Ltd.)
It is commercially available at. Its standard properties are a 1% by weight dispersion in water with a pH of 5-5.5, a particle size of 200 meshes, and a degree of substitution of carboxymethyl groups per anhydroglucose unit of 0.55-0.6. Fibrin calcium glycolate in tablet form:
It is used in an amount of 2 to 15% based on the total weight to give it disintegrability, but it has relatively poor fluidity among powder compositions, and has a diameter of 3 to 20 mm and a depth of 7 to 10 mm.
Bridges tend to form in the mm tableting machine, which tends to reduce the quantitative supply of raw material powder and granules. This low quantitative feedability causes fluctuations in tablet weight, amount of medicinal ingredients, and tablet hardness, and is unfavorable in terms of workability and quality control. The inventors of the present invention found that the quantitative feedability of this powder composition largely depends on the bulk specific gravity of the cellulose calcium glycolate used, and found that the cellulose calcium glycolate having a large bulk specific gravity was used. The present invention was achieved by recognizing that when used, the powder composition for tablet molding has good quantitative supply properties, and tablets without fluctuations in weight or hardness can be obtained. The method for producing cellulose calcium glycolate, which has a large bulk density and is used in the present invention, is basically based on the
According to the method disclosed in Publication No. 43-7960, the free acid form of cellulose glycolic acid is obtained by reacting calcium carbonate in a wet state. By setting the degree of substitution to be high and the degree of neutralization to a high pH range, it is possible to obtain cellulose calcium glycolate having a large bulk specific gravity. In addition, increasing the stirring air during the neutralization reaction and replacing about 1/3 of the calcium carbonate used for neutralization with calcium hydroxide are also favorable conditions for obtaining cellulose calcium glycolate with a large bulk specific gravity. . The bulk specific gravity of the cellulose calcium glycolate used in the present invention is 550 to 900 g/. If the bulk specific gravity is 550 g/or less, it is the same as when using a conventional commercially available product. On the other hand, it is better to have a larger bulk specific gravity, but it is difficult to manufacture a bulk specific gravity of 900g/or more.
Moreover, uniform mixing properties with other components in the powder composition may deteriorate. The bulk specific gravity referred to here is a value measured using the following method for a powder sample. Bulk specific gravity measurement method Prepare a 200ml graduated cylinder and add 200ml of powder sample.
Gradually add to the ml mark and layer. Lift the graduated cylinder so that the distance between the bottom and the floor is 5 cm, release your hand, and let the cylinder fall. After repeating this operation 10 times and reading the volume (ml), weigh the powder sample. Bulk specific gravity (g/) = [Weight (g)/Volume (ml)] x 1000 The present invention will be specifically explained below with reference to Examples. Example 1 and Comparative Example 1 Powder composition using cellulose calcium glycolate with different bulk specific gravity as a disintegrant, ascorbic acid as a medicinal ingredient, and microcrystalline cellulose (Avicel PH101, manufactured by Asahi Kasei) as an excipient. Tablets were molded from the material by direct compression method. The powder composition and tableting conditions are as follows. Powder composition Ascorbic acid 50.0 Avicel (200mesh impermeable) 42.0 Disintegrant 5.0 Talc 2.5 Magnesium stearate 0.5 100.0% by weight Tableting conditions Tableting machine: Rotary powder molding machine No. 8F-3B Kikusui Seisakusho Molding conditions: Tablet diameter: 7.6 mm Thickness: approx. 4.0 mm Powder is supplied to the molding machine using an open feed, and the tablets are compressed by changing the powder filling depth and tableting pressure level, and the average weight and weight deviation of the tablets (n = 30 ),
The average hardness, hardness deviation (n=5), degree of abrasion, and collapsibility were measured. However, the methods for measuring hardness, abrasion and disintegration are as follows. Hardness: Monsanto hardness meter Abrasion level: Kayagaki type abrasion tester 25 rotations, 20 minutes processing 100 tablets were processed and powdered, and the weight is expressed as a percentage. Disintegration: Disintegration tester according to the Japanese Pharmacopoeia (Toyama Sangyo Co., Ltd.) Measurement temperature: 37 ± 2°C Test liquid: Water and Pharmacopoeia No. 1 liquid (artificial gastric fluid) n = 10: Average value of the time required for disintegration show.
(Seconds) Table 1 shows the properties of cellulose calcium glycolate used as a disintegrant. ( * However, the degree of neutralization is expressed as the pH of the medium when the sample is dispersed in 100 times the volume of distilled water.)
【表】
錠剤物性測定結果を第2表に示す。
[Table] Table 2 shows the results of measuring the physical properties of the tablets.
【表】
嵩比重の大きい崩壊剤(No.2)を使用した実施
例1の錠剤は比較例1の錠剤(No.1はECG−505
規格相当品)に比べて重量変動が明らかに小さ
い。また硬度はやゝ大きい傾向を示したがこれは
実施例1の方が比較例1よりも充填性(粉体流動
性)が良好なためと考えられる。
実施例2〜3 比較例2
実施例1と比較例1のアスコルビン酸に代えて
薬効成分としてアスピリンを用い、同様の打錠試
験を行なつた。
粉粒体組成
アスピリン(100mesh不通過) 55.0
アビセル(200mesh不通過) 37.1
崩壊剤 5.0
タルク 2.4
ラブリーワツクス 0.5
100.0重量%
第2表に崩壊剤として使用した繊維素グリコー
ル酸カルシウムの性状を示す。[Table] The tablets of Example 1 using a disintegrant with high bulk specific gravity (No. 2) are the tablets of Comparative Example 1 (No. 1 is ECG-505).
The weight fluctuation is clearly smaller than that of standard equivalent products). Furthermore, the hardness tended to be slightly higher, but this is thought to be because Example 1 had better filling properties (powder fluidity) than Comparative Example 1. Examples 2 to 3 Comparative Example 2 A similar tableting test was conducted using aspirin as the medicinal ingredient in place of ascorbic acid in Example 1 and Comparative Example 1. Powder composition Aspirin (100mesh does not pass) 55.0 Avicel (200mesh does not pass) 37.1 Disintegrant 5.0 Talc 2.4 Lovely Wax 0.5 100.0% by weight Table 2 shows the properties of cellulose calcium glycolate used as a disintegrant.
【表】
錠剤物性測定結果を第4表に示す。
但し、重量測定個数は50、硬度測定個数は20と
した。[Table] Table 4 shows the results of measuring the physical properties of the tablets. However, the number of weight measurements was 50 and the number of hardness measurements was 20.
【表】
嵩比重の大きい崩壊剤を使用した実施例2と3
の錠剤は、比較例2の錠剤に比べ重量変動が小さ
く、充填性(粉体流動性)が良好なものであると
考えられる。[Table] Examples 2 and 3 using disintegrants with high bulk specific gravity
It is thought that the tablets had smaller weight fluctuations than the tablets of Comparative Example 2 and had better filling properties (powder fluidity).
Claims (1)
加えられる添加剤からなる粉粒体組成物におい
て、崩壊剤が嵩比重550g/以上900g/以下
の繊維素グリコール酸カルシウムであることを特
徴とする錠剤用粉粒体組成物。1. A powder or granular composition consisting of a medicinal ingredient, an excipient, a disintegrant, and additives added as necessary, characterized in that the disintegrant is calcium cellulose glycolate with a bulk specific gravity of 550 g/- to 900 g/- A powder composition for tablets.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15874183A JPS6048934A (en) | 1983-08-29 | 1983-08-29 | Powdery composition for tablet |
| US06/643,648 US4508893A (en) | 1983-08-25 | 1984-08-23 | Process for the preparation of a powdery calcium cellulose glycolate |
| DE3431227A DE3431227C2 (en) | 1983-08-25 | 1984-08-24 | Process for the preparation of powdered calcium cellulose glycolate |
| KR1019840005131A KR900004699B1 (en) | 1983-08-25 | 1984-08-24 | Preparation of Powdered Fibrin Glycool Calcium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15874183A JPS6048934A (en) | 1983-08-29 | 1983-08-29 | Powdery composition for tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6048934A JPS6048934A (en) | 1985-03-16 |
| JPH0465813B2 true JPH0465813B2 (en) | 1992-10-21 |
Family
ID=15678318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15874183A Granted JPS6048934A (en) | 1983-08-25 | 1983-08-29 | Powdery composition for tablet |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6048934A (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53127553A (en) * | 1977-04-13 | 1978-11-07 | Asahi Chem Ind Co Ltd | Vehicle |
| JPS59176217A (en) * | 1983-03-28 | 1984-10-05 | Daicel Chem Ind Ltd | Powder composition for solid pharmaceutical preparation |
| JP3032234B2 (en) * | 1990-04-20 | 2000-04-10 | 株式会社日立製作所 | Alignment device |
-
1983
- 1983-08-29 JP JP15874183A patent/JPS6048934A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6048934A (en) | 1985-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6383835B2 (en) | Cellulose powder | |
| MX2012002789A (en) | Antacid and laxative tablet. | |
| ZA200006440B (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates. | |
| JP2011526612A (en) | Orally disintegrating mannitol | |
| JP6630229B2 (en) | Levetiracetam-containing pharmaceutical composition and method for producing the same | |
| JP4446177B2 (en) | Method for producing moisture-resistant orally disintegrating tablets | |
| JP2009524658A (en) | Levetiracetam preparation and method for producing the same | |
| JP4702763B2 (en) | Stable tablets containing crystalline cellulose | |
| JP4015485B2 (en) | Antacid / loose tablets | |
| WO1999036097A1 (en) | Disintegrating agent | |
| JP2001114703A (en) | Solid preparation and production method thereof | |
| KR101813065B1 (en) | Solid formulation comprising alginic acid and/or alginate | |
| JPH0465813B2 (en) | ||
| JP4774739B2 (en) | Kampo extract-containing tablet composition and method for producing the same | |
| JP5710301B2 (en) | Orally disintegrating tablet and method for producing the same | |
| JP2017052754A (en) | Method for producing orally disintegrating tablet, and granules used for the same | |
| TWI637749B (en) | Disintegrating particle composition produced in two-stage wet granulation step and oral disintegrating tablet containing the composition | |
| JP2018118963A (en) | Pharmaceutical composition containing memantine or pharmacologically acceptable salt thereof and method for producing the same, and agent and method for improving the quality of pharmaceutical composition containing memantine or pharmacologically acceptable salt thereof | |
| JPH0526770B2 (en) | ||
| JP6341196B2 (en) | Solid preparation | |
| JPS60152424A (en) | Solid preparation | |
| JP3310233B2 (en) | Disintegrant for tablets | |
| JP2524497B2 (en) | Persistent solid agent | |
| JPH02286614A (en) | Acetoaminophene preparation | |
| Jha et al. | Development of natural gum based fast disintegrating tablets of glipizide |